Thalidomide off-label coverage
"I think we are making a lot of progress" in working with CMS to gain coverage for thalidomide for cancer in replacement drug demonstration project under Medicare Part B, Sen. Kay Bailey Hutchison (R-Tex.) tells the Blood Cancer Coalition May 19. Under CMS proposed demonstration, Medicare would cover only FDA-approved indications for oral cancer drugs (1"The Pink Sheet" April 19, 2004, p. 29). Thalidomide (Celgene's Thalomid) is approved only for the cutaneous symptoms of leprosy but is widely used for multiple myeloma...
You may also be interested in...
Reimbursement for oral chemotherapy products under a Medicare Part B demonstration project will be limited to FDA-approved indications, the Centers for Medicare & Medicaid Services' proposed criteria say
Teva has launched the first and so far only US generic version of Novartis’ Azopt treatment for ocular hypertension, with the brinzolamide 1% solution having been developed and manufactured by Indoco Remedies.
There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.